Mr. Michael Frank reports

REVIVE THERAPEUTICS ANNOUNCES FILING OF PATENT FOR BUCILLAMINE IN THE TREATMENT OF EXPOSURE TO CHEMICAL WARFARE AGENTS

Revive Therapeutics Ltd. has filed a provisional patent application titled "Compositions, methods and uses of Bucillamine in the treatment of a victim exposed to a chemical warfare agent."

The methods and compositions described in the patent application relate to bucillamine as a potential treatment of a victim exposed to a chemical agent, including chemical warfare agents such as sulphur mustards, nitrogen mustards, nerve agents of G and V types, lewisite, and adamsite. According to the U.S. Department of Homeland Security, a chemical attack is the spreading of toxic chemicals with the intent to do harm, which may include chemical weapons (warfare agents) developed for military use, toxic industrial and commercial chemicals that are produced, transported and stored in the making of petroleum, textiles, plastics, fertilizers, paper, foods, pesticides, household cleaners, and other products, and chemical toxins of biological origin such as ricin.

The company is commencing to work with advisers in developing a strategic plan to present its case in repurposing bucillamine as a potential medical countermeasure for chemical warfare agent exposures to the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services.

At this time, the company will only provide regular updates through press releases as information becomes available.

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the U.S. Food and Drug Administration (FDA) such as orphan drug, fast-track, breakthrough therapy and rare pediatric disease designations. Currently, the company is exploring the use of bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

We seek Safe Harbor.